Article
Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials.
Oncology - 1 Jan 2011
Blanco Codesido Montserrat, Tesainer Brunetto Andre, Frentzas Sophia, Moreno Garcia Victor, Papadatos-Pastos Dionysis, Pedersen Joanna Vitfell, Trani Leonardo, Puglisi Martina, Molife L Rhoda, Banerji Udai
Abstract excerpt
INTRODUCTION: First-line treatment options utilizing chemotherapy and cytokine-based treatments for patients with metastatic melanoma (MM) are unsatisfactory. We analyzed the clinical outcomes of patients with MM treated in phase I trials of novel agents. We hypothesized that patients included in phase I clinical trials did not have worse outcomes than with the chemotherapy and cytokine-based first-line...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.